Carasent ASA (CARA) - Net Assets
Based on the latest financial reports, Carasent ASA (CARA) has net assets worth Skr792.47 Million SEK (≈ $85.28 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr973.10 Million ≈ $104.72 Million USD) and total liabilities (Skr180.63 Million ≈ $19.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Carasent ASA balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr792.47 Million |
| % of Total Assets | 81.44% |
| Annual Growth Rate | 12.52% |
| 5-Year Change | -31.02% |
| 10-Year Change | 1547.33% |
| Growth Volatility | 86.44 |
Carasent ASA - Net Assets Trend (2002–2025)
This chart illustrates how Carasent ASA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Carasent ASA market capitalisation.
Annual Net Assets for Carasent ASA (2002–2025)
The table below shows the annual net assets of Carasent ASA from 2002 to 2025. Also explore Carasent ASA equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr808.00 Million ≈ $86.95 Million |
-6.67% |
| 2024-12-31 | Skr865.73 Million ≈ $93.17 Million |
-9.39% |
| 2023-12-31 | Skr955.41 Million ≈ $102.82 Million |
-22.11% |
| 2022-12-31 | Skr1.23 Billion ≈ $132.00 Million |
+4.72% |
| 2021-12-31 | Skr1.17 Billion ≈ $126.05 Million |
+192.11% |
| 2020-12-31 | Skr400.98 Million ≈ $43.15 Million |
+342.69% |
| 2019-12-31 | Skr90.58 Million ≈ $9.75 Million |
-0.94% |
| 2018-12-31 | Skr91.43 Million ≈ $9.84 Million |
+49.24% |
| 2017-12-31 | Skr61.27 Million ≈ $6.59 Million |
+24.91% |
| 2016-12-31 | Skr49.05 Million ≈ $5.28 Million |
-31.37% |
| 2015-12-31 | Skr71.47 Million ≈ $7.69 Million |
-12.74% |
| 2014-12-31 | Skr81.90 Million ≈ $8.81 Million |
-37.38% |
| 2013-12-31 | Skr130.79 Million ≈ $14.08 Million |
+13.88% |
| 2012-12-31 | Skr114.85 Million ≈ $12.36 Million |
+0.71% |
| 2011-12-31 | Skr114.03 Million ≈ $12.27 Million |
+6.98% |
| 2010-12-31 | Skr106.59 Million ≈ $11.47 Million |
-12.22% |
| 2009-12-31 | Skr121.43 Million ≈ $13.07 Million |
-16.19% |
| 2008-12-31 | Skr144.89 Million ≈ $15.59 Million |
+20.53% |
| 2007-12-31 | Skr120.21 Million ≈ $12.94 Million |
-34.80% |
| 2006-12-31 | Skr184.38 Million ≈ $19.84 Million |
+162.34% |
| 2005-12-31 | Skr70.28 Million ≈ $7.56 Million |
+36.17% |
| 2004-12-31 | Skr51.61 Million ≈ $5.55 Million |
+22.48% |
| 2003-12-31 | Skr42.14 Million ≈ $4.54 Million |
-21.30% |
| 2002-12-31 | Skr53.55 Million ≈ $5.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Carasent ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5979300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr500.00K | 0.06% |
| Other Components | Skr867.29 Million | 107.34% |
| Total Equity | Skr808.00 Million | 100.00% |
Carasent ASA Competitors by Market Cap
The table below lists competitors of Carasent ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Can2 Termik AS
IS:CANTE
|
$192.84 Million |
|
Polymetals Resources Ltd
AU:POL
|
$192.90 Million |
|
Hong Leong Capital Bhd
KLSE:5274
|
$192.99 Million |
|
Unison Co. Ltd
KQ:018000
|
$193.07 Million |
|
Hwacom Systems
TWO:6163
|
$192.80 Million |
|
STILLFRONT GRP AB SK-07
F:1YS0
|
$192.76 Million |
|
Orient Group Inc
SHG:600811
|
$192.74 Million |
|
Verb Technology Company Inc
NASDAQ:VERB
|
$192.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carasent ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 865,725,782 to 808,002,000, a change of -57,723,782 (-6.7%).
- Net income of 34,670,000 contributed positively to equity growth.
- Share repurchases of 108,430,000 reduced equity.
- New share issuances of 1,502,000 increased equity.
- Other factors increased equity by 14,534,218.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr34.67 Million | +4.29% |
| Share Repurchases | Skr108.43 Million | -13.42% |
| Share Issuances | Skr1.50 Million | +0.19% |
| Other Changes | Skr14.53 Million | +1.8% |
| Total Change | Skr- | -6.67% |
Book Value vs Market Value Analysis
This analysis compares Carasent ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.94x to 2.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr28.56 | Skr26.80 | x |
| 2003-12-31 | Skr18.13 | Skr26.80 | x |
| 2004-12-31 | Skr20.65 | Skr26.80 | x |
| 2005-12-31 | Skr26.33 | Skr26.80 | x |
| 2006-12-31 | Skr55.07 | Skr26.80 | x |
| 2007-12-31 | Skr27.49 | Skr26.80 | x |
| 2008-12-31 | Skr24.34 | Skr26.80 | x |
| 2009-12-31 | Skr13.68 | Skr26.80 | x |
| 2010-12-31 | Skr5.24 | Skr26.80 | x |
| 2011-12-31 | Skr5.60 | Skr26.80 | x |
| 2012-12-31 | Skr5.62 | Skr26.80 | x |
| 2013-12-31 | Skr6.42 | Skr26.80 | x |
| 2014-12-31 | Skr4.04 | Skr26.80 | x |
| 2015-12-31 | Skr3.53 | Skr26.80 | x |
| 2016-12-31 | Skr2.41 | Skr26.80 | x |
| 2017-12-31 | Skr3.01 | Skr26.80 | x |
| 2018-12-31 | Skr2.25 | Skr26.80 | x |
| 2019-12-31 | Skr2.23 | Skr26.80 | x |
| 2020-12-31 | Skr8.93 | Skr26.80 | x |
| 2021-12-31 | Skr17.45 | Skr26.80 | x |
| 2022-12-31 | Skr15.35 | Skr26.80 | x |
| 2023-12-31 | Skr12.29 | Skr26.80 | x |
| 2024-12-31 | Skr11.97 | Skr26.80 | x |
| 2025-12-31 | Skr11.65 | Skr26.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carasent ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.08%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.16x
- Recent ROE (4.29%) is above the historical average (-14.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -194.29% | -829.29% | 0.21x | 1.13x | Skr-109.39 Million |
| 2003 | -102.31% | -194.99% | 0.45x | 1.16x | Skr-47.33 Million |
| 2004 | -92.14% | -126.40% | 0.58x | 1.26x | Skr-52.72 Million |
| 2005 | -60.41% | -77.09% | 0.39x | 2.01x | Skr-49.48 Million |
| 2006 | -20.19% | -27.92% | 0.48x | 1.50x | Skr-55.66 Million |
| 2007 | -115.23% | -65.84% | 0.95x | 1.84x | Skr-150.54 Million |
| 2008 | -39.74% | -24.60% | 0.95x | 1.69x | Skr-72.06 Million |
| 2009 | -16.82% | -8.16% | 1.29x | 1.60x | Skr-32.57 Million |
| 2010 | -17.15% | -8.05% | 1.16x | 1.84x | Skr-28.94 Million |
| 2011 | 3.68% | 1.73% | 1.21x | 1.76x | Skr-7.21 Million |
| 2012 | 6.15% | 2.95% | 1.13x | 1.85x | Skr-4.42 Million |
| 2013 | 3.63% | 1.87% | 1.13x | 1.72x | Skr-8.33 Million |
| 2014 | -96.13% | -26.93% | 1.29x | 2.77x | Skr-87.47 Million |
| 2015 | 83.70% | 19.91% | 1.39x | 3.02x | Skr53.04 Million |
| 2016 | 289.08% | 73.18% | 3.85x | 1.02x | Skr136.89 Million |
| 2017 | 33.15% | 0.00% | 0.00x | 1.01x | Skr14.18 Million |
| 2018 | -7.69% | -29.35% | 0.20x | 1.30x | Skr-16.18 Million |
| 2019 | 3.55% | 6.70% | 0.35x | 1.51x | Skr-5.85 Million |
| 2020 | -9.51% | -54.03% | 0.14x | 1.26x | Skr-78.23 Million |
| 2021 | -0.01% | -0.11% | 0.11x | 1.11x | Skr-117.28 Million |
| 2022 | 2.54% | 15.96% | 0.14x | 1.12x | Skr-91.49 Million |
| 2023 | -4.86% | -19.04% | 0.22x | 1.14x | Skr-141.99 Million |
| 2024 | -4.73% | -15.35% | 0.26x | 1.20x | Skr-127.55 Million |
| 2025 | 4.29% | 10.08% | 0.37x | 1.16x | Skr-46.13 Million |
Industry Comparison
This section compares Carasent ASA's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $95,807,737
- Average return on equity (ROE) among peers: 16.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carasent ASA (CARA) | Skr792.47 Million | -194.29% | 0.23x | $192.82 Million |
| Aino Health AB (AINO) | $1.98 Million | 73.96% | 3.57x | $4.36 Million |
| Kontigo Care AB (KONT) | $17.72 Million | -37.94% | 0.52x | $4.87 Million |
| Medhelp Care AB (MEDHLP) | $8.68 Million | 33.82% | 4.47x | $22.60 Million |
| Physitrack PLC (PTRK) | $1.35 Million | -5.77% | 0.39x | $15.47 Million |
| RaySearch Laboratories AB (publ) (RAY-B) | $118.07 Million | 30.68% | 0.24x | $580.09 Million |
| Surgical Science Sweden AB (SUS) | $427.05 Million | 3.65% | 0.11x | $270.17 Million |
About Carasent ASA
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient comm… Read more